Globus Medical (GMED) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales reached $629.7M, up 115.9% year-over-year, driven by the NuVasive merger and strong organic growth in spine and enabling technologies.

• Non-GAAP EPS was $0.75, up 20% despite a 35% increase in share count from the merger; GAAP net income was $31.8M, down from $57.7M in Q2 2023 due to higher integration and restructuring costs.

• Integration of Globus and NuVasive field organizations is progressing, with new reporting structures, combined product portfolios, and operational initiatives.

• Multiple new products launched year-to-date, with a record number of launches expected in the coming months.

• The NuVasive merger, completed in September 2023, significantly expanded the product portfolio and global reach.

Financial highlights

• Q2 revenue was $629.7M, up 115.9% as reported and 117.3% on a constant currency basis.

• GAAP net income was $31.8M ($0.23 per diluted share); non-GAAP net income was $102.7M ($0.75 per diluted share), up 61.5% year-over-year.

• Adjusted EBITDA margin was 30.2%; free cash flow was $26.5M.

• Musculoskeletal revenue grew to $592.9M; enabling technologies revenue was $36.8M.

• U.S. revenue was $499.5M, up 103.5%; international revenue was $130.2M, up 182.3%.

• GAAP gross profit margin was 58.7%, down from 73.8% due to step-up amortization from the merger; adjusted gross profit margin was 67.2%.

Outlook and guidance

• 2024 net sales expected between $2.47B and $2.49B, implying 3.1%-3.9% growth over 2023 pro forma revenues.

• Non-GAAP EPS guidance raised to $2.80-$2.90, representing 20.7%-25% growth over prior year.

• Full-year adjusted gross profit rate expected in the mid to upper sixties; long-term goal to return to mid-seventies.

• R&D expense for 2024 expected at 6.5%-7% of sales; SG&A expenses to improve 1-2 percentage points over 2023.

• CapEx for 2024 projected at 4.5%-5.5% of sales.